Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

454 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Safety and immunogenicity of the adjunct therapeutic vaccine ID93 + GLA-SE in adults who have completed treatment for tuberculosis: a randomised, double-blind, placebo-controlled, phase 2a trial.
Day TA, Penn-Nicholson A, Luabeya AKK, Fiore-Gartland A, Du Plessis N, Loxton AG, Vergara J, Rolf TA, Reid TD, Toefy A, Shenje J, Geldenhuys H, Tameris M, Mabwe S, Bilek N, Bekker LG, Diacon A, Walzl G, Ashman J, Frevol A, Sagawa ZK, Lindestam Arlehamn C, Sette A, Reed SG, Coler RN, Scriba TJ, Hatherill M; TBVPX-203 study team. Day TA, et al. Among authors: reed sg. Lancet Respir Med. 2021 Apr;9(4):373-386. doi: 10.1016/S2213-2600(20)30319-2. Epub 2020 Dec 8. Lancet Respir Med. 2021. PMID: 33306991 Clinical Trial.
Safety and immunogenicity of the novel tuberculosis vaccine ID93 + GLA-SE in BCG-vaccinated healthy adults in South Africa: a randomised, double-blind, placebo-controlled phase 1 trial.
Penn-Nicholson A, Tameris M, Smit E, Day TA, Musvosvi M, Jayashankar L, Vergara J, Mabwe S, Bilek N, Geldenhuys H, Luabeya AK, Ellis R, Ginsberg AM, Hanekom WA, Reed SG, Coler RN, Scriba TJ, Hatherill M; TBVPX-114 study team. Penn-Nicholson A, et al. Among authors: reed sg. Lancet Respir Med. 2018 Apr;6(4):287-298. doi: 10.1016/S2213-2600(18)30077-8. Lancet Respir Med. 2018. PMID: 29595510 Clinical Trial.
Second-generation vaccines against leishmaniasis.
Coler RN, Reed SG. Coler RN, et al. Among authors: reed sg. Trends Parasitol. 2005 May;21(5):244-9. doi: 10.1016/j.pt.2005.03.006. Trends Parasitol. 2005. PMID: 15837614 Review.
New horizons in adjuvants for vaccine development.
Reed SG, Bertholet S, Coler RN, Friede M. Reed SG, et al. Trends Immunol. 2009 Jan;30(1):23-32. doi: 10.1016/j.it.2008.09.006. Epub 2008 Dec 6. Trends Immunol. 2009. PMID: 19059004 Review.
A clinical trial to evaluate the safety and immunogenicity of the LEISH-F1+MPL-SE vaccine for use in the prevention of visceral leishmaniasis.
Chakravarty J, Kumar S, Trivedi S, Rai VK, Singh A, Ashman JA, Laughlin EM, Coler RN, Kahn SJ, Beckmann AM, Cowgill KD, Reed SG, Sundar S, Piazza FM. Chakravarty J, et al. Among authors: reed sg. Vaccine. 2011 Apr 27;29(19):3531-7. doi: 10.1016/j.vaccine.2011.02.096. Epub 2011 Mar 15. Vaccine. 2011. PMID: 21414377 Clinical Trial.
454 results